港股药明康德今日盘中股价大涨5.47%,引发市场高度关注。
据了解,药明康德公司在整个医药市场竞争加剧的背景下,为了控本并集中资源用于优势领域,近期纷纷出售了一些资产。同时公司宣布出售旗下控股子公司药明合联7.17%的股份,从而获取超过20亿元收益。这笔资金将用于加速推进全球产能及能力建设,吸引和留住优秀人才,持续强化公司在药品领域的一体化CRDMO(合同研究、开发和生产组织业务)模式。
投资者对于药明康德加大布局CRDMO业务的举动表示欢迎。这一举措有助于公司进一步聚焦主业,加快一体化CRDMO业务的发展,从而增强其长期增长潜力。同时注资也有利于公司吸引并培养优秀人才,在行业内保持领先优势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.